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Abstract
Ion channels and ion fluxes control many aspects of tissue homeostasis. During oncogenic transformation, critical ion
channel functions may be perturbed but conserved tumor specific ion fluxes remain to be defined. Here we used the
tumoricidal protein-lipid complex HAMLET as a probe to identify ion fluxes involved in tumor cell death. We show that
HAMLET activates a non-selective cation current, which reached a magnitude of 2.7460.88 nA within 1.4360.13 min from
HAMLET application. Rapid ion fluxes were essential for HAMLET-induced carcinoma cell death as inhibitors (amiloride,
BaCl2), preventing the changes in free cellular Na
+ and K+ concentrations also prevented essential steps accompanying
carcinoma cell death, including changes in morphology, uptake, global transcription, and MAP kinase activation. Through
global transcriptional analysis and phosphorylation arrays, a strong ion flux dependent p38 MAPK response was detected
and inhibition of p38 signaling delayed HAMLET-induced death. Healthy, differentiated cells were resistant to HAMLET
challenge, which was accompanied by innate immunity rather than p38-activation. The results suggest, for the first time, a
unifying mechanism for the initiation of HAMLET’s broad and rapid lethal effect on tumor cells. These findings are
particularly significant in view of HAMLET’s documented therapeutic efficacy in human studies and animal models. The
results also suggest that HAMLET offers a two-tiered therapeutic approach, killing cancer cells while stimulating an innate
immune response in surrounding healthy tissues.
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Introduction
Ion channels are a prerequisite for normal cell function. They
are highly conserved through evolution, and are activated by a
wide variety of signals including mechanical forces, voltage, pH,
matrix interactions and growth factor receptor activity
[1,2,3,4,5,6]. As a result, ion channels facilitate cellular adaptation
to different physical environments, by adjusting proliferation and
apoptosis, organ development and homeostasis. Ion channel
activation has been proposed to regulate the activity of essential
cellular signaling cascades, including p38 mitogen-activated
protein kinases (MAPKs), small guanine triphosphate hydrolases
(GTPases), the phosphatidyl-inositol-3-kinase (PI3K)-Akt pathway,
NFkB- and Ca2+-dependent signaling pathways [7,8]. Recently,
ion channel dysregulation has been proposed to also promote
malignant transformation, tumorigenesis and metastasis, suggest-
ing a central role of ion channels for cancer development. Indeed,
a wide range of ion channels, including Ca2+, K+, Na+, and Cl2
channels, and non-selective cation channels, have been implicated
in various aspects of cancer development (for reviews, see
[1,9,10,11,12,13,14,15]).
HAMLET (human alpha-lactalbumin made lethal to tumor
cells) is the first member of a new family of tumoricidal molecules
with remarkable properties. Formed from partially unfolded a-
lactalbumin and with oleic acid as an integral constituent [16,17],
HAMLET was discovered by serendipity when studying the ability
of human milk to prevent bacteria from binding to host cells. Early
in vitro experiments showed that HAMLET displays broad anti-
tumor activity with a high degree of tumor selectivity [16,17].
Subsequent therapeutic studies in patients and animal models have
confirmed HAMLETs tumoricidal activity and relative selectivity
for tumor tissue in vivo. HAMLET treatment delayed tumor
progression and led to increased survival in a rat glioblastoma
xenograft model without evidence of cell death in healthy brain
tissue [18]. Topical HAMLET administration removed or reduced
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the size of skin papillomas, as shown using a placebo-controlled
protocol with a two-year follow up [19]. Local instillation of
HAMLET in patients with bladder cancer rapidly killed tumor
cells without toxic effects on healthy tissues surrounding the tumor
[20] and therapeutic efficacy of HAMLET was demonstrated in a
murine bladder cancer model [21]. Recently, peroral HAMLET
administration has shown therapeutic as well as prophylactic
efficacy against colon cancer in APC min mice (GUT, in press).
The sensitivity to HAMLET at least in part reflects increased c-
Myc oncogene expression and dysregulated glycolysis in tumor
cells [22], but the specific membrane interactions that initiate the
HAMLET-induced cell death process have not been defined.
Cellular responses to HAMLET are quite rapid compared to cell
death inducers like FAS ligand or TNF-a [23], implying a more
immediate and general mechanism for HAMLET sensing at the
cell membrane than via traditional extrinsic apoptosis induction.
In early studies, we detected rapid Ca2+ fluxes after tumor cell
exposure to HAMLET [17], suggesting that ion channels and/or
transporters might be activated. Recently, dramatic changes in the
structure of artificial, receptor-free membranes and plasma
membrane vesicles from cancer cells have been observed after
HAMLET challenge [24]. Rounded, defined vesicles changed
morphology to amorphous shapes, reflecting the formation of long
membrane distensions with increased fluidity. A similar response
to HAMLET was observed in plasma membrane vesicles from
carcinoma cells, suggesting that direct membrane effects might
contribute to the tumoricidal effect of HAMLET. Normal
differentiated cells showed no evidence of membrane perturbation
[24], suggesting that the membrane perturbations might charac-
terize HAMLET sensitive tumor cells.
This study characterized ion fluxes triggered by HAMLET and
examined their role in tumor cell death. We show that HAMLET
activates a whole cell non-selective cation current, which we
characterize electrophysiologically. Importantly, we show that ion
fluxes are essential to initiate HAMLET-induced tumor cell death
and to distinguish tumor cells from normal cells in this context.
The effects of HAMLET on cancer cell viability were reversed by
amiloride or BaCl2, non-specific inhibitors of several ion channels
and transporters. In parallel, changes in morphology, ion fluxes,
global transcription, MAPK signaling and p38 MAPK-dependent
tumor cell death were also abrogated. Furthermore, the response
of normal, differentiated cells to HAMLET showed marked
differences from that of cancer cells, defined by the pattern of
changes in global transcription, signaling pathway activation and
survival. The establishment of a non-selective, amiloride-sensitive
cation channel as essential to HAMLET-induced cancer cell death
describes a hitherto unresolved mechanism and may represent a
new therapeutic option.
Materials and Methods
HAMLET Production
a-Lactalbumin was purified from defatted human milk by
ammonium sulfate precipitation and hydrophobic interaction
chromatography and converted to HAMLET by partial unfolding
and binding to oleic acid, as previously described [16]. Briefly,
native a lactalbumin was dissolved in Tris (10 mM Tris/HCl
pH 8.5) and Ca2+ was removed by the addition of 3.5 mM EDTA.
The partially unfolded protein was applied to a DEAE-Trisacryl
M matrix pre-conditioned with oleic acid at pH 8.5 (Sigma
Aldrich, St. Louis, MO). The HAMLET complex was eluted with
a NaCl gradient. Dialysis was used to remove excess salt and
HAMLET was lyophilized and stored at 220uC. The purity of
each HAMLET batch was confirmed by SDS PAGE (Nupage,
Invitrogen) and activity by quantifying cell death, as described
below.
Human milk was obtained from individual donors, after signed
informed consent. Each donor was aware that the samples may be
used in scientific research. The samples were de-identified and
steps were taken to protect the participants’ identities. The
procedure was approved by the human ethics committee of the
Medical Faculty, Lund University, Lund, Sweden.
Cells
To identify conserved response pathways explaining the broad
tumoricidal effects of HAMLET [25] tumor cells differing in tissue
origin, oncogene repertoire, cell membrane composition, ion
channel expression and growth capacity were used. T-cell
lymphoma cells (Jurkat), lung carcinoma (A549), ovarian carcino-
ma (HeLa) and kidney (A498) carcinoma cells (ATCC, Manassas,
VA) were cultured in RPMI-1640 with non-essential amino acids
(1:100), 1 mM sodium pyruvate, gentamicin (50 mg/ml, Gibco,
Paisley, UK), and 5% (A549 and Jurkat) or 10% (HeLa and A498)
fetal calf serum (FCS, Gibco), respectively. Healthy, differentiated
human renal epithelial cells (HRTEC) in primary culture were
kindly provided by Prof. D. Karpman (Lund University, Lund,
Sweden) after ethical approval from the Medical Ethics Commit-
tee of the Lund University Medical Faculty (decision number LU
456–96). These cells have previously been shown to be resistant to
the lethal effects of HAMLET [16]. HRTECs were cultured in
DMEM/F12 with 15% FCS (as in [26]) Primary RPTEC cells
(human renal proximal tubule epithelial cells) were purchased
from Lonza (Basel, Switzerland) and cultured in DMEM-F12
supplemented with NEAA, sodium pyruvate, gentamicin, gluta-
max and 15% FBS (Gibco).
Cell Death Assays
Carcinoma cells were detached from cell culture flasks with
Versen (0.2 g EDTA in 200 ml H2O and 800 ml PBS) washed
with PBS and resuspended in serum-free RPMI-1640. Cells were
seeded at a density of 50.000/well in a 24-well plate and allowed
to adhere overnight in growth medium. HAMLET dissolved in
PBS was incubated with cells in serum-free medium and FCS was
added after 1 hour. Jurkat cells in suspension (.80% viable) were
mixed with HAMLET at 37uC at a density of 106/ml in serum-
free media. All cell death measurements were carried out three
hours after HAMLET addition, unless otherwise stated. Cell death
was quantified by trypan blue exclusion (Chroma Gesellschaft
Schmid & Co) by counting of at least 300 cells/sample or by
measuring ATP levels (ATPlite Kit, PerkinElmer, Infinite F200,
Tecan). Light images were captured using the HoloMonitorTM
M2 digital holographic microscope (Phase Holographic Imaging
AB, Lund, Sweden). Trypan blue is a classical vital dye, reflecting
the loss of membrane integrity in dying cells. ATP is widely used as
a surrogate biochemical marker for viability, based on the
assumptions that living cells produce ATP and it is indispensable
for cellular life [27]. HAMLET treated cells have previously been
examined for evidence of programmed cell death, including
apoptosis and autophagy [28,29]. While caspases and autophagy
are activated in HAMLET treated cells, inhibition of these
pathways does not rescue the cells from HAMLET-induced death.
Therefore apoptotic and autophagic parameters are unlikely to
explain the HAMLET-induced effects and were not examined in
this study.
Intracellular Ion Concentrations and Ion Fluxes
The relative, free intracellular concentrations of Ca2+ ([Ca2+]i)
and Na+ ([Na+]i) were estimated using the calcium indicator
Ion Channel Activation and Tumour Cell Death
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Fluo-4 NW and the sodium fluorophore CoroNa Green,
respectively (Invitrogen). For Ca2+ measurements, A549 cells
were given fresh medium with Fluo-4 NW (5 mM) and
incubated at 37uC for 30 min, and subsequently treated as
indicated. Fluo-4 fluorescence was measured at 535 nm after
excitation at 485 nm using a fluorescence plate reader (TECAN
infinite F200, Tecan Group, Switzerland). The Ca2+ ionophore
A23187 (1 mM, Invitrogen) was used as a positive control.
Relative [Na+]i was measured in Jurkat cells by loading the cells
with the sodium indicator CoroNa Green (Invitrogen) at 10 mM
for 30 min. For estimation of K+ fluxes, the FluxORTM
potassium ion channel assay (Invitrogen) was used according
to the manufacturer’s instructions. Briefly, cells were incubated
with FluxORTM, which is a Tl+ indicator. An increase in
fluorescence signal corresponds to an influx of Tl+, indicating
opening of potassium channels, which was measured at 535 nm
after excitation at 485 nm in the TECAN infinite plate reader.
K+ fluxes and [Ca2+]i were additionally analyzed by confocal
imaging. Images were captured every 10 s for 5 min on a
LSM510 META confocal microscope (520 nm emission after
excitation at 488 nm).
Patch Clamp Measurements
Solutions. The standard extracellular solution contained (in
mM): 150 NaCl, 6 CsCl, 2 MgCl2, 1 CaCl2, 10 HEPES, 10
glucose and pH was adjusted to 7.4 using NaOH. The pipette
solution for standard measurement contained (in mM): 20 CsCl,
100 Cs-aspartate, 1 MgCl2, 0.08 CaCl2, 10 HEPES, 10 1,2-bis(2-
aminophenoxy)ethane-N,N,N’,N’-tetraacetate (BAPTA), 4 Na2-
ATP and pH was adjusted to 7.2 using CsOH. The free calcium
concentration of this solution is ,200 nM. For estimation of the
relative permeability of monovalent cations the extracellular
solution contained: (in mM) 20 CsCl, 130 XCl, 10 HEPES and
10 glucose where X represents the respective monovalent cation
(Na+, K+, or Cs+). All solutions were adjusted to pH 7.4 using Tris.
The pipette solution for selectivity measurements was: (in mM)
100 Cs-aspartate, 20 XCl, 10 HEPES and 10 glucose, with
X = Na+, K+, or Cs+4 Na2-ATP and 5 ethylene glycol tetraacetic
acid (EGTA) with X = Na+, K+, or Cs+. pH was adjusted to 7.2
using Tris. To maintain ionic composition, HAMLET, a-
lactalbumin and oleate were directly dissolved into recording
solutions.
Electrophysiological recording. For patch clamp measure-
ments, A549 cells where seeded on round coverslips 24–48 h
before measurement. All measurements were conducted at room
temperature with constant perfusion. Whole cell currents were
measured using an EPC10-USB amplifier (HEKA Elektronik,
Lambrect, Germany), employing ruptured patches. Pipette resis-
tance was 6.560.4 MV in asymmetrical solutions. Capacitance
and series resistance were recorded continuously and 65% of the
series resistance was electronically compensated to reduce voltage
errors. As reference electrode, Ag-AgCl electrode was used under
standard conditions while a 3 M KCl agar bridge was used for
selectivity measurements. All measurements where performed
using a 400 ms linear voltage ramp from 2100 mV to +100 mV.
The protocol was initiated by a 50 ms prepulse at 2100 mV and
followed by 1550 ms at –30 mV. All data were filtered 2.9 kHz
and sampled 1 kHz.
Calculation of the relative permeability. Due to the
relatively narrow window of time from HAMLET stimulation to
seal rupture (presumably reflecting membrane perturbation by
HAMLET, see Results), relative permeability ratios were calcu-
lated from the absolute reversal potentials (Vrev) using the equation
[30]:
Px
PCs
~
Csz½ e{ Csz½ ieVrevF=RT
Xz½ ieVrevF=RT{ Xz½ e
where PX represents gives the permeability of the given ion [X
+]i,
[X+]e represents the intracellular and extracellular concentrations,
and F, T, R has their normal values. The relative Ca2+
permeability was calculated as [30]:
PCa
PCs
~(1zeVrevF=RT )|
( Csz½ iza Naz½ i)eVrevF=RT{ Csz½ e{a Naz½ e
4 Ca2z½ e
in which a= PNa/PCs.
Before calculations, Vrev was corrected for liquid junction
potentials [31] (VLJ) as:
Vcorrected~Vmeasured{VLJ
VLJ was calculated using the built-in JPCalcW software in
Clampex7 (Axon Instruments, USA).
Confocal Microscopy
For confocal microscopy, cells were cultured overnight on 8-well
chamber slides (Nalge Nunc A/S, Roskilde, Denmark). After the
respective experimental procedures, cells were fixed in 3.7%
paraformaldehyde, nuclei and plasma membrane were stained
with Draq5 (eBiosciences) and Alexa-Fluor 488-labeled wheat
germ agglutinin (Invitrogen) and examined in a LSM510 DUO
confocal microscope using a 636 oil immersion objective (Carl
Zeiss, Jena, Germany). The 488 nm Argon laser line was used to
excite Alexa-Fluor 488 fluorescence, which was detected using a
band pass filter from 505 to 530 nm. Alexa-Fluor 568 was excited
using the HeNe543 nm laser, and fluorescence was detected using
a band-pass filter from 560 to 615 nm. The 633 nm HeNe laser
was used to excite Draq5, and fluorescence was measured using a
650 long-pass filter. For ion channel inhibition, cells were pre-
incubated with medium containing inhibitors for 30 minutes and
treated with 35 mM HAMLET (3.5 mM Alexa-Fluor 568-labeled
HAMLET (Invitrogen, Carlsbad, CA) and 31.5 mM unlabeled
HAMLET) in serum-free medium. For live cell imaging, cells were
maintained at 37uC, nuclei were stained with Hoechst 33342
(Invitrogen) and Alexa-Fluor 568-labeled HAMLET was added in
serum-free medium. The cells were kept at 37uC, 5% CO2 and
images were collected regularly by confocal microscopy, using a
LSM510 META (Carl Zeiss, Jena, Germany).
Transcriptomic Analysis
For the microarray analysis, 200.000 A549 cells/well were
allowed to adhere overnight on a 6-well plate. After 1 h of
HAMLET treatment (21 mM), attached as well as floating cells
were lysed and RNA was extracted using the RNeasy Mini Kit
(QIAGEN). The samples were sent to AROS Applied Biotech-
nology (A˚rhus, Denmark) for analysis and run on Human Genome
U219 Array Plate according to standard Affymetrix protocols.
Data analysis was carried out using R and Bioconductor (http://
www.r-project.org). The raw data was normalized using RMA
(Irizarry et al., 2003) in which raw intensities are background-
corrected, log2 transformed and then normalized using quantiles.
Ion Channel Activation and Tumour Cell Death
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A linear model is fitted to the data to obtain expression value for
each probe set. The normalized data was found to be of excellent
quality with high replicate correlation (.0.99) and NUSE
(normalized unscaled errors) values close to 1 (range 0.994–
1.008). To derive differentially expressed genes a linear model was
fitted using the Bioconductor limma package and genes with
empirical Bayes adjusted p-values ,0.05 and log2 fold changes
.1 were considered differentially expressed and were functionally
characterized using the Database for Annotation, Visualization
and Integrated Discovery (DAVID; (Dennis et al., 2003) and
Ingenuity Pathway Analysis. For the extended microarray analysis,
gene expression was assessed by whole genome Illumina micro-
arrays (HumanHT-12 Expression BeadChip). Data was normal-
ized using cross-correlation [32]. Genes with a Benjamini-
Hochberg adjusted p-value ,0.05 and log2 fold change $1.2 in
tumor cells and $2.0 in normal, differentiated cells at any time
point were regarded as differentially expressed. All microarray
data were registered into NCBI’s Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/projects/geo)
with accession number GSE23772.
Western Blots and Cytokine Quantification
For Western blots, 200.000 cells were allowed to adhere
overnight in a 6-well plate, exposed to different experimental
conditions and lysed in M-PER lysis buffer (Pierce, Rockford, IL)
containing Complete Protease Inhibitor Cocktail and PhosSTOP
phosphatase inhibitor cocktail (both from Roche, Mannheim,
Germany). The lysates were cleared by centrifugation and protein
concentrations were measured using the DC Protein Assay (Bio-
Rad Laboratories, Hercules, CA) on a Tecan Infinite plate reader.
Equal amounts of protein were separated by SDS-PAGE on 4–
12% Bis-Tris gels (Invitrogen) and blotted onto PVDF membranes
(GE Healthcare). Membranes were saturated with BSA (GAPDH),
nonfat dry milk (phospho-p38 MAPK, p38 MAPK, phospho-
ERK1/2, ERK1/2, ATF6, phospho-eIF2a) or Sat-1 and Sat-2 (a-
lactalbumin) and incubated with anti-bovine a-lactalbumin (1:500,
Bethyl Laboratories, Montgomery, Texas), anti-p38 MAPK, anti-
phospho-(Thr180/Tyr182)p38 MAPK, anti-ERK1/2, anti-phos-
pho-(Thr202/Tyr204)-ERK, anti-phospho-eIF2a (Ser51) (all
1:500–1000, Cell Signaling Technology, Danvers, MA), anti-
ATF6 (1:1000, IMG-273, Imgenex) or anti-GAPDH (1:3000–
5000, Novus Biologicals) antibodies followed by horseradish
peroxidase-conjugated anti-rabbit (1:1000, DakoCytomation,
Glostrup, Denmark), anti-goat (1:1000, Sigma Aldrich) or anti-
mouse (1:40.000–50.000, Novus Biologicals) secondary antibodies
for staining. Bound antibodies were detected with ECL Plus
Western Blotting Reagent (GE Healthcare, Little Chalfont, UK)
and GelDoc equipment (Bio-Rad Laboratories, Hercules, CA). To
control for equal loading, membranes were stripped with Restore
Western Blot Stripping Buffer (Pierce), blocked and reprobed with
new antibodies. For siRNA experiments, equal volumes of lysates
were separated by SDS-PAGE on 4–12% Bis-Tris gels (Invitrogen)
and blotted onto PVDF membranes.
MAPK phosphorylation was analyzed on a Human Phospho-
MAPK array (Proteome Profiler Array, R&D Systems, Minneap-
olis, MN) as per the manufacturer’s instructions. Band and spot
intensities were quantified using ImageJ [33]. Cytokine quantifi-
cation (IL-6, IL-8, TNF-a) was performed on an IMMULITE
1000 immunoassay system (Siemens Diagnostics, Deerfield, IL).
Inhibitors and RNAi
Pharmacologic ion channel inhibitors are widely used as tools to
define the function of specific ion channel classes. Amiloride
inhibits several Na+-carrying channels and transporters, incl.
ENaC type Na+ channels, Na+/H+ exchangers, and Na+/Ca2+
exchangers. Barium chloride (BaCl2) blocks many types of
potassium channels. Gadolinium chloride (GdCl3) is a general
inhibitor of mechanosensitive channels and tetrandrine inhibits
large conductance Ca2+ activated potassium channels. Ruthenium
Red is a broad inhibitor of many cation channels including
intracellular Ca2+ release channels. Amiloride (1 mM), BaCl2,
(1 mM), Ruthenium Red (30 mM), tetrandrine (10 mM) and GdCl3
were from Sigma Aldrich. For p38 MAPK inhibition, SB202190
(20 mM, Sigma Aldrich) or BIRB796 (10 mM, Axon Medchem)
were used.
For RNA interference, FlexiTube siRNA Premixes against
MAPK11 (SI00606053), MAPK14 (SI00300769) and All Star
Negative Control siRNA (SI03650318) from QIAGEN (Hilden,
Germany) were used. A549 cells were forward transfected using a
25 nM final siRNA concentration in 24-well plates. For p38
MAPK, knockdown was examined by Western blot and RT-PCR
48 h after transfection.
Statistical Analysis
Repeated measures ANOVA or two-sided Students t-test were
applied as relevant and were performed with InStat software
(version 3.06, GraphPad, San Diego, CA). Test for normality was
done using InStat, using the Kolmogorov-Smirnov test. For all
experiments, a p-value ,0.05 was considered significant. The
error bars in all graphs represent SEMs from at least three
independent biological replicates.
Results
Na+, K+and Ca2+ Fluxes Induced by HAMLET in Tumor
Cells
Changes in intracellular ion concentrations induced by HAM-
LET (35 mM) in tumor cells were characterized by fluorometry
(Figure 1A) and real time confocal imaging (Figure 1B). HAMLET
triggered a rapid increase in [Na+]i in Jurkat cells preloaded with
the Na+ fluorophore CoroNa Green. Opening of a plasma
membrane K+ transport pathway in response to HAMLET was
recorded in A549 lung carcinoma cells using the FluxORTM assay,
which monitors the influx of thallium as a surrogate marker for K+
[34]. Given the driving force for K+ flux across the plasma
membrane this corresponds to K+ efflux, assuming that the
transport pathway is a channel (see Discussion). HAMLET also
triggered a rapid and sustained increase in [Ca2+]i in Fluo-4AM
preloaded lung carcinoma cells (Figure 1A). In contrast, native a-
lactalbumin or oleic acid did not induce Na+, K+or Ca2+ fluxes
(Figure 1A).
The [Ca2+]i and K
+ ion fluxes were also visualized using
confocal microscopy and shown to occur in almost all cells
(Figure 1B). These rapid ion fluxes were not observed by confocal
microcopy in healthy, differentiated cells in primary culture
(HRTEC). Confocal imaging of Fluo-4 loaded cells revealed a
difference in kinetics and magnitude between responses to
HAMLET or the Ca2+ ionophore A23187 (Figure 1C), suggesting
that they work by distinct mechanisms. Ca2+-chelation with
EGTA had little effect on the increase in [Ca2+]i, suggesting that
the involvement of extracellular Ca2+ was minimal (Figure 1D).
However, inhibition of InsP3-gated ER Ca2+ channels with
U73122 essentially abolished the increase in [Ca2+]i, implying
that it originated mainly from intracellular stores (Figure 1D, [35]).
Ion Channel Activation and Tumour Cell Death
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HAMLET-induced Ion Fluxes are Amendable to Ion
Channel Inhibitors
A panel of well-characterized ion channel inhibitors was used to
further investigate the HAMLET induced ion fluxes. The change
in [Na+]i in Jurkat cells was inhibited by amiloride and BaCl2, the
K+ flux in lung carcinoma cells by BaCl2 and the Ca
2+ flux by
amiloride and BaCl2 (Figure 1E). The effect of amiloride on the
K+ flux could not be tested, due to autofluorescence. The
molecular nature of the HAMLET-activated current was further
investigated using the broad-spectrum Ca2+ channel inhibitors,
Ruthenium red and tetrandrine, none of which significantly
affected the current (Figure 1E).
HAMLET Activates a Nonselective Whole Cell Cation
Current in Carcinoma Cells
The observed changes in intracellular ion concentrations were
indicative that HAMLET activated a non-selective ion channel.
This hypothesis was confirmed by whole cell patch clamp
experiments (Figure 2). HAMLET (35 mM) activated a whole cell
current, which reached a magnitude of 2.7460.88 nA within
1.4360.13 min. The current exhibited a rather linear current-
voltage-relationship (Figure 2A,B) and a clear time-dependent
inactivation at depolarized potentials (Figure 2C). Initial current
activation exhibited a delay of 0.8860.13 min from HAMLET
application. In contrast, a-lactalbumin or oleate, were inactive,
emphasizing the need for the HAMLET complex to activate the
cell current (Figure 2A–B). The reversal potential (Vrev) in Cs-
based solutions was 25.160.99 mV, corresponding to the
calculated Nernst potential 4.85 mV while Vrev was
28.361.3 mV and 2.462 mV in Na+ and K+ based solutions,
respectively, giving a permeability ratio of PCs (1).PK
(0.8860.1).PNa (0.4860.03) (Figure 2D). As HAMLET was
insoluble in high Ca2+ solutions and the time between application
and cell rupture due to membrane incorporation (see later) did not
allow for solution exchange, Pca was not measurable. However, in
Ca2+ free medium, the rate of the HAMLET induced increase in
[Ca2+]i was reduced, suggesting at least a minor Ca
2+ permeability
of the channel. The current was inhibited by the non-specific
cation channel inhibitor amiloride (Figure 2E), and was blocked in
a voltage-dependent manner by BaCl2 (Figure 2F).
The characteristics of the HAMLET-induced current are at
variance with the biophysical and pharmacological characteristics
of most widely expressed cation channels such as the transient
receptor potential (TRP), epithelial Na+ channel (ENaC) and
various K+ channel families. While the biophysics and pharma-
cology showed some similarity to the cyclic-nucleotide-gated
(CNG) channels [36], which are expressed and functional in
A549 cells [37], the inclusion of 8-Br-cGMP (1 mM) in the pipette
solution activated a current with different biophysical properties.
Furthermore, a CNG-channel inhibitor did not affect the
HAMLET-induced current (L-cis-diltiazem, LCD (200 mM, Fig-
ure S1) or the death, confirming that CNG channels are not major
HAMLET targets (Figure S1E).
In a further attempt to identify the channel, a broad range of
methods was applied. By gene expression analysis (see below),
the ion channel repertoire of tumor cells and healthy cells was
compared. The expression of around 400 ion channel genes was
surveyed in exponentially growing lunch carcinoma (A549) and
kidney carcinoma (A498) cells using Illumina whole genome
arrays. The ion channel mRNA repertoire was also compared
to that of Human Renal Proximal Tubular Epithelial Cells
(HRPTEC) in primary culture. As expected, only a fraction of
the ion channels in the human genome was expressed in each
tumor cell line (around 5%, defined as a 3-fold change above
the background). The cell lines expressed one constitutively
active Na+ channel (SCNN1A) and one voltage-gated Na+
channel (SCN3A) as well as about 200 voltage-gated K and
Ca2+ channels with no major differences in the number or level
of expressed ion channel genes between carcinoma cells and
normal cells. Furthermore, an ion channel ligand library
containing 69 ion channel blockers and openers was used for
further characterizing and identifying ion channels in individual
cells affecting the response to HAMLET. However, no single
inhibitor, other than those previously identified (Amiloride and
BaCl2) was able to reproducibly alter HAMLET’s effect. Thus,
using these technologies, no conclusive target was identified,
further indicating that the channel activated by HAMLET
exhibits some unusual properties, perhaps reflecting a novel
subunit composition, cancer-cell specific alternative splicing or a
HAMLET induced channel (see Discussion).
Interestingly, application of HAMLET increased cell capac-
itance from 24.561.1 pF to 30.461.5 pF (n = 7, p,0.001)
(Figure 2A, lower panel). The temporal pattern correlated
closely with that of the induced current (Figure 2A, upper
panel). The current was also activated when HAMLET was
applied directly to inside-out membrane patches, further
supporting a direct effect at the level of HAMLET at the
plasma membrane (Figure 2G). Collectively, the results strongly
suggest that HAMLET’s membrane-perturbing effects may be
the trigger for channel activation.
Ion Channel Inhibition Prevents HAMLET-induced Cell
Death
The ion channel inhibitors were further used to examine
whether ion fluxes are important for the tumoricidal activity of
HAMLET. Lung carcinoma cells were pretreated for 30 min with
amiloride, BaCl2, Ruthenium red or tetrandrine, and exposed to
HAMLET (21–35 mM, 3 h). Changes in cell viability were
quantified by two techniques. The trypan blue exclusion assay
detects the accumulation of vital dye secondary to changes in
Figure 1. HAMLET alters intracellular ion concentrations in tumor cells. (A) Estimates of the relative free, intracellular concentrations of Na+,
K+, and Ca2+ ([Na+]i, [K
+]i, and [Ca
2+]I, respectively) were obtained in A549 cells (K
+ and Ca2+) and Jurkat cells (Na+) by fluorescence spectrometry using
CoroNa Green, FluxOR and Fluo-4. Rapid ion fluxes were detected and these effects were HAMLET specific, as a-lactalbumin, oleic acid or PBS had no
effect. (Means of four experiments, p,0.05 (Students t-test at t = 2 minutes) (B) Difference in HAMLET-induced ion fluxes between tumor cells and
healthy cells. Ca2+ and K+ fluxes are visualized by real time confocal imaging of A549 lung carcinoma cells and HRTEC healthy, differentiated kidney
cells, loaded with the Ca2+ and K+ fluorophores and treated with HAMLET (35 mM) for up to 290 seconds. Representative figures from three
experiments are shown. (C) Calcium ionophore (A23187, 1 mM) response in A549 lung carcinoma cells loaded with Fluo-4. Representative figure from
three experiments. (D) Inhibition of intracellular calcium release from ER reduces Ca2+ fluxes. A549 cells were pretreated with a PLC-inhibitor (10 mM,
U73122), its inactive analogue (10 mM, U73343) or EDTA (1 mM) for 30 minutes and treated with HAMLET as indicated. Means of three experiments.
(E) Amiloride (Amil, 1 mM) inhibited Na+ and Ca2+ fluxes in A549 cells (Ca2+) and Jurkat cells (Na+) induced by HAMLET (marked as H in figure). BaCl2
(1 mM) inhibited the Na+, K+ and Ca2+ fluxes. Cells were pre-loaded with the respective fluorophores, pretreated with inhibitors (30 minutes) and
challenged with HAMLET (35 mM) for up to 5 minutes. Effects of amiloride on K+ fluxes could not be determined due to auto fluorescence. Ruthenium
red (RR, 30 mM) reduced Ca2+ fluxes while tetranidrine (Tet, 10 mM) had no significant effect.
doi:10.1371/journal.pone.0058578.g001
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Figure 2. Whole cell currents activated by HAMLET in lung carcinoma cells. HAMLET-induced currents were recorded in A549 cells, by
whole cell patch clamp analysis, with the exception of data in G, which were obtained in inside-out patches. (A) Top panel: Currents were measured
using the described ramp protocol and currents measured at +100 mV and 2100 mV are depicted as a function of time for three representative and
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membrane integrity in dying cells [38]. Cellular ATP levels are
widely used as a surrogate biochemical marker for viability [27].
The rapid, dose-dependent loss of viability in response to
HAMLET was detected by both techniques with similar kinetics
(Figure 3A–B). Inhibition of ion fluxes by amiloride or BaCl2,
reduced cell death from about 50% to,20% (p,0.05) (Figure 3A–
B).
The reversal of cell death by amiloride and BaCl2 was
confirmed in ovarian carcinoma cells (HeLa cells) and lymphoma
cells (Jurkat cells), under the same experimental conditions (Figures
S2A, B and S3A, B). Furthermore, the rescue effect of amiloride or
BaCl2 on carcinoma cells was sustained. About 80% of the tumor
cells had died after 24 h of HAMLET treatment (35 mM) but cells
pretreated with amiloride or BaCl2 remained viable (9% and 34%
cell death, respectively, Figure S3C) and combining both ion
channel inhibitors completely rescued the cells from HAMLET-
induced death (Figure S3D).
To further address if extracellular Ca2+ contributes to the cell
death response, the cytotoxic effect of HAMLET was tested in
Ca2+-free medium. While the tumoricidal effect of HAMLET was
unchanged in the absence of Ca2+, combining amiloride and
BaCl2 still prevented HAMLET-induced death (Figure S3D). The
tumoricidal effect of HAMLET was also unchanged by U73122, a
phospholipase C inhibitor, which consequently blocks Ca2+ release
from the ER via the inositol trisphosphate (InsP3) receptor channel
(Figure S3E). In congruence with their lack of effect on [Na+]i and
[K+]i, neither Ruthenium red nor tetranidrine rescued lung
carcinoma, ovarian carcinoma or lymphoma cells from HAM-
LET-induced cell death (Figure 3A, S2 and S3).
Collectively, these results suggest that HAMLET triggers rapid
[Na+]i and [K
+]i fluxes by activation of an amiloride- and Ba
2+-
sensitive, nonselective cation channel and that these effects are
essential for HAMLET-induced cell death.
Ion Channel Inhibition Prevents HAMLET-induced
Morphological Change and HAMLET Internalization
HAMLET treated carcinoma cells internalize large amounts of
HAMLET [39]. To address if ion fluxes are involved in the
internalization process, the internalization of Alexa 568-labeled
HAMLET by lung carcinoma cells was quantified in the presence
or absence of Amiloride or BaCl2, (Figure 3C, S4). Internalization
was markedly reduced by amiloride or BaCl2, and the inhibitory
effect was confirmed by western blots of whole cell extracts (35 mM
HAMLET, 1 h, Figure 3E). In parallel, the change in morphology,
which characterizes the response to HAMLET, was also reduced
(Figure 3C–D). Neither of the ion channel inhibitors had any
detectable effect on the morphology of the cells in the absence of
HAMLET (not shown).
These results suggest that ion fluxes activated by HAMLET
control both HAMLET internalization and the HAMLET-
induced changes in tumor cell morphology.
Ion Fluxes Influence the Transcriptional Response to
HAMLET
Gene expression profiling technology is used to define how
cellular responses affect transcription and to predict resulting
phenotypes, including those involved in cell death [40]. The global
transcriptional response to HAMLET was therefore examined,
using whole genome arrays, before and after exposure of
carcinoma cells to HAMLET (35 mM, 1 h). Hierarchical cluster-
ing of the top 3000 genes by variance (Figure 4A) and differential
expression analysis detected 336 differentially expressed genes
(Adjusted p-value ,0.05 and Fold change .1, Figure 4A–B) in
response to HAMLET. Main regulated gene categories were
involved in cell death, chromatin regulation or ER stress. Strongly
regulated pathways were identified by Ingenuity pathway analysis
and DAVID. Top scoring pathways were p38 MAPK-signaling
(Enrichment Score (ES) = 6.7, n = 15), cell death (ES = 4.7, n = 22)
and ER stress (ES = 2.2, n = 8).
To address if ion fluxes control the global transcriptional
response to HAMLET (35 mM, 1 h), lung carcinoma and
kidney carcinoma cells were pretreated with amiloride and
exposed to HAMLET, as described above. Amiloride dramat-
ically reduced the transcriptional response to HAMLET (32
differentially genes remained differentially expressed, p,0.001,
Figure 4B) and the p38 MAPK-signaling-, cell death- or ER
stress pathways were no longer significantly regulated, suggesting
that ion fluxes orchestrate most of the early transcriptional
response to HAMLET.
The p38 MAPK Dependent Death Response to HAMLET
Marked p38 MAPK-signaling was detected 1 and 6 h after
exposure to HAMLET (Figure 5A). The activated p38 MAPK
components included MKK3, a direct upstream activator of p38
MAPK along with 8 other p38 MAPK pathway genes (Figure 5B)
and two dual-specificity phosphatases (DUSPs; DUSP1 and
DUSP10) with log2-fold changes of 1.34 and 1.98, respectively.
DUSPs are feedback regulators of MAPK signaling, and are up-
regulated when the pathway is active [41]. Upregulated genes
downstream of p38 MAPK included CREB5, CHOP and
HIST2H3C. After 24 hours, transcriptional activity returned to
baseline levels except for IRAK2, PLA2G4C, CHOP and
CREB5, which sustained elevated expression. Other activated
genes were involved in cell death (ATF3, DDX3X, DDIT3,
HSPA1) and chromatin structure (DNAJB3, GADD45A/B,
HIST1H1C, KLF2/4/6) regulation [39].
independent experiments stimulated with a-lactalbumin, oleate or HAMLET, the presence of which in the superfusate is indicated by the top line.
Lower panel: Cell capacitance as a function of time. Same experiments as in top panel. (B) Same experiments as in A, showing the current- voltage
relationship of cells following the indicated stimulation. The control trace represents the current-voltage relationship before exposure to HAMLET
(n = 7). (C) Using a 1 s protocol stepping from 2100 mV to +100 mV in 20 mV increments, time dependent characteristics of the HAMLET activated
current were investigated. Note the clear time dependent inactivation at strongly depolarized potentials. n = 3. (D) Selectivity profile of HAMLET
activated currents. Top panel: Reversal potentials of HAMLET activated currents where estimated from individual experiments as described in
Materials and Methods. Lower panel: Permeability ratios for Na+ and K+ relative to Cs+, calculated as described. n = 3–5 (E) Amiloride inhibits HAMLET
activated currents. Left panel: Current magnitude measured at 2100 mV and +100 mV. The presence of amiloride (1 mM) and HAMLET in the
superfusate is indicated by the top lines. Compare the current with that in the absence of amiloride in (A). Right panel: Current-Voltage relationship
from same experiment as in the left panel. n = 4. (F) BaCl2 partially blocks the inward current. Left panel: Current magnitude measured at 2100 mV
and +100 mV. The presence of BaCl2 (1 mM) and HAMLET in the superfusate is indicated by the top lines. Right panel: Current-Voltage relationship
from the same experiment as in left panel. Note the strong inhibition of the inward current compared to the outward current. n = 3. (G) HAMLET
stimulates current activation in inside-out patches. Left Panel: Currents in inside-out patches were followed at the holding potential of the described
ramp protocol and plotted as a function of time. The presence of HAMLET in the perfusion solution is indicated above. Right panel: Current voltage
relationship measured in inside-out patches in the presence and absence of HAMLET. Same experiments as in the left panel. n = 3.
doi:10.1371/journal.pone.0058578.g002
Ion Channel Activation and Tumour Cell Death
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58578
Ion Channel Activation and Tumour Cell Death
PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e58578
The p38 MAPKs are activated by dual phosphorylation on
conserved threonine and tyrosine residues by MKK3/6. Down-
stream effector proteins include MAPKAPK2 kinase, heat shock
protein 27 (HSP27), and the transcription factors ATF2 and
CHOP [42]. HAMLET triggered rapid (30 minutes) p38a and
HSP27 phosphorylation in lung and kidney carcinoma cells
(Figure 5C, D; phosphoarray images given in Figure S6A, B). In
addition, p38b and p38c were phosphorylated in kidney
carcinoma cells (Figure 5C). In parallel, a loss of ERK1/2
phosphorylation occurred in both cell types (Figure 5C, D),
consistent with a shift from cell proliferation to cell death [43], and
with the known inhibitory effect of p38 MAPK on ERK activity
after stress stimuli [44]. In contrast, HAMLET had no detectable
effect on the phosphorylation of JNK kinase (Figure S6A, B).
Phosphorylation of p38 MAPK was confirmed by Western
blotting and was dose- and time- dependent (Figure 5E).
To address if p38 MAPK signaling is involved in HAMLET-
induced cell death p38a and p38b were inhibited in lung
carcinoma, kidney carcinoma and lymphoma cells. SB202190 is
a highly specific pyridinyl-imidazole inhibitor and BIRB796 a
diaryl urea compound, which bears little structural similarity to
SB202190. The tumoricidal response to HAMLET was attenuated
by SB202190 (Figure 6A, B) or BIRB796 (Figure S6E, F),
accompanied by a marked decrease in p38 MAPK and HSP27
phosphorylation (Figure S6C). By real-time confocal imaging, p38
MAPK inhibition (SB202190) was shown to delay the morpho-
logical response to HAMLET for about six hours and internalized
Alexa-Fluor labeled HAMLET was delayed (Figure 6C). Further-
more, HAMLET-induced cell death was inhibited by the
combined siRNA knockdown of p38a and p38b with knockdown
efficacy confirmed by qRT-PCR and western blot (Figure 6D–F).
Each siRNA alone was ineffective, however, indicating that each
isoform is sufficient to induce cell death.
Ion Channel Inhibitors Block HAMLET-induced p38
MAPK-phosphorylation in Tumor Cells
To examine whether ion channels control responses to
HAMLET through effects on p38 signaling, tumor cells were
pretreated with ion channel inhibitors and p38 MAPK-, and
ERK1/2 phosphorylation in response to HAMLET was quanti-
fied using phospho-specific antibodies. Amiloride and BaCl2
reduced HAMLET-induced p38 MAPK-phosphorylation in lung
carcinoma cells (Figure 7A) and in parallel, the reduction in
ERK1/2 phosphorylation was reversed (Figure 7B). These results
suggest that the p38 MAPK pathway orchestrates the early death
response to HAMLET.
Normal, differentiated cells survive HAMLET with an
innate immune response. Notably, healthy differentiated cells
in primary culture (HRTEC) showed minimal increase in dual-
phosphorylated (Thr180/Tyr182) p38 MAPK in response to
HAMLET treatment, in marked contrast to kidney carcinoma
cells (A498), where more than a 40-fold increase in p38 MAPK
phosphorylation was detected (Figure 7C). The p38 MAPK
pathway was intact in the healthy cells, however, as osmotic shock
Figure 3. Ion channel inhibitors rescue carcinoma cells from death and block HAMLET uptake and morphologic change. (A, B)
Viability of lung carcinoma cells after exposure to HAMLET (21 or 35 mM, 3 h), quantified by trypan blue exclusion and ATP levels. Amiloride or BaCl2
inhibited the tumoricidal effect of HAMLET but Ruthenium Red and tetrandrine showed no effect (means+SEMs, two to three experiments per
condition). (C) Internalization of Alexa-568 fluor labeled HAMLET by tumor cells (35 mM, 1 hour), visualized by high magnification (x63) confocal
microscopy. HAMLET was localized to peri-nuclear and nuclear regions in tumor cells. Amiloride or BaCl2 inhibited internalization, leaving HAMLET
associated with the cell surface. HAMLET was labeled red (Alexa-568), nuclei blue (Draq5) and membranes were labeled green (WGA). Scale
bar = 10 mM. (D) BaCl2 and amiloride prevented changes in carcinoma cells morphology in response to HAMLET (Mean of two images in one
experiment+SEMs). Rounding up signifies the shift from an adherent, extended to a rounded morphology. (E) Western blot of cell lysates confirming
the reduction in cell-associated HAMLET by amiloride and BaCl2 (35 mM, 1 hour, detected with anti-a-lactalbumin antibodies, ALA). GAPDH was used
as a loading control.
doi:10.1371/journal.pone.0058578.g003
Figure 4. The transcriptomic response to HAMLET requires functional ion channels. Genome wide expression analysis in lung carcinoma
cells stimulated with HAMLET in the presence or absence of Amiloride. (A) Heatmap of the normalized expression of top 3000 genes sorted according
to variance across all conditions. Amiloride markedly reduced the global transcriptional response to HAMLET but had little effect on control cells. (B)
Scatter plots of normalized expression values for all genes present on the array. The number of differentially expressed genes (log2 fold change .1
and FDR-adjusted p-value ,0.05, marked in black) was greatly reduced by amiloride.
doi:10.1371/journal.pone.0058578.g004
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Figure 5. HAMLET activates the p38 MAPK signaling pathway. (A) Transcriptional changes were identified in HAMLET-treated A549 lung
carcinoma cells. Three hundred sixty-seven genes showed a minimum log 2-fold change of 1.2 compared to PBS-treated control cells, with a
Benjamini-Hochberg adjusted p-value ,0.05. Ten genes in the p38 pathway were upregulated (red) three hours after HAMLET treatment (21 mM) of
lung carcinoma cells (A549), as marked in the canonical pathway. (B) Heat map (triplicate for each time period) and log2 ratios of differentially
expressed genes in the p38 MAPK pathway, 1, 3, 6 and 24 hours after HAMLET exposure. (D, E) Increased phosphorylation of p38a, b, c or HSP27 and
reduced ERK1/2 phosphorylation in kidney (C) and lung (D) carcinoma cells exposed to HAMLET (35 mM, 30 minutes). Membranes with phospho-
specific antibodies were probed with protein lysates from HAMLET- or PBS-treated (control) carcinoma cells. Protein phosphorylation was quantified
using ImageJ. Data are mean 6 SEM of 3 experiments. Full array images are given in Figure S6. (E) Dose- and time-dependent p38 MAPK
phosphorylation in response to HAMLET. Lung carcinoma cells were treated with HAMLET and compared to PBS-treated negative controls and whole
cell lysates were probed with antibodies specific for phosphorylated p38 MAPK (Thr180/Tyr182). Membranes were stripped and reprobed with total
p38 and GAPDH antibody as a loading control. For effects on p38 MAPK signaling in kidney carcinoma cells, see Figure S6.
doi:10.1371/journal.pone.0058578.g005
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by 300 mM NaCl (30 min), which was used as a positive control,
induced a 19-fold increase in p38 MAPK phosphorylation.
The difference between tumor cells and healthy, differentiated
cells was further examined by comparing the transcriptional
responses to HAMLET (35 mM, 1 h) in A498 kidney carcinoma
and healthy differentiated kidney cells. Gene expression was much
less strongly affected (2064 versus 4424 genes in kidney carcinoma
cells, Figure 8A, 35 mM, 1 h) and healthy cells exhibited a
transient, rather than a sustained response (Figure 8A,B). No p38
MAPK- or HSP27 phosphorylation was detected (Figure S6D). In
A498 kidney carcinoma cells, the p38 MAPK pathway again
emerged as the top-scoring canonical pathway (Figure S5),
confirming the results from lung carcinoma cells. The p38 MAPK
signaling pathway genes were down-regulated in healthy, differ-
entiated cells at early time points, with decreased expression of
MKK3 and p38 MAPK after 60 and 75 min of HAMLET
exposure (Figure 8C). Moreover, other death-related signaling
pathways showed no significant regulation by HAMLET in
normal, differentiated cells.
Pathways significantly regulated by HAMLET in normal cells
were involved in innate immune regulation (IL-6 pathway,
Figure 8C) and glucocorticoid signaling. Prominently upregulated
genes included IL-1, IL-6, c-Jun, c-Fos, IkB and TNF-a.
HAMLET also triggered IL-6, IL-8, and TNF-a secretion in
healthy, differentiated cells but not in carcinoma cells (Figure 8D).
The innate immune response to HAMLET in normal, differen-
tiated cells was shown to require ion channels (Figure 8E).
Amiloride abolished the increase in IL-6 and similar results were
seen for IL-8 and TNF-a. BaCl2 reduced HAMLET- induced
TNF-a expression but did not inhibit the IL-6 and IL-8 responses.
These results suggest that through differential ion channel
activation, HAMLET stimulates different biological end points in
tumor cells and normal, differentiated cells.
Discussion
Ion channels are frequently dysregulated in human cancers due
to gene amplifications, epigenetic regulation or splice variants of
ion channel-encoding genes (for reviews, see [1,9,10,11,12]).
Targeting ion fluxes should thus be a feasible strategy for anti-
cancer therapy and a recent high throughput small molecule
screen identified a tumoricidal potassium ionophore, particularly
effective against cancer stem cells [45]. The therapeutic potential
of ion channel modulators remains underexploited, however, due
in part to a lack of tumor-specific channel modulators. Here, we
identify a novel, non-selective cation channel in HAMLET treated
tumor cells and provide evidence that the death response of tumor
cells to HAMLET is caused, in part, by ion fluxes, initiating a
broad and eventually lethal response, which distinguished
carcinoma cells from normal, differentiated cells. This tumor-
selective death through ion channel perturbation is particularly
interesting, as it suggests a unifying mechanism for tumor cell
death.
HAMLET perturbs the structure of biological membranes [24].
Artificial membranes composed of egg yolk or soybean lipids and
lacking protein receptors responded to HAMLET with shape
change, elongation and increased fluidity. The lipid or protein
alone did not show these effects, suggesting that the complex has
unique membrane integration properties. In addition, leakage of
vesicular contents has been detected, suggesting that the mem-
branes barrier function is altered by HAMLET [24,46]. Mechan-
osensitive ion channels are membrane proteins that undergo a
conformational change in response to mechanical forces that alter
membrane tension voltage, pH, matrix interactions and growth
factor receptor activity [47] and such channels respond to stretch
along the plane of the membrane, in the absence of ‘‘specific’’
receptors [48]. Based on its direct effects on lipid bilayers, effects of
HAMLET on the mechanosensing homeostasis are likely to occur.
The observed inside out activation of ion fluxes by HAMLET is
consistent with this hypothesis, as specific membrane orientation
was not required for such fluxes to be initiated. If HAMLET itself
is involved in channel formation, a direct interaction of HAMLET
with the ion channel blockers may also occur.
One K+, Na+ and Ca2+-permeable, nonselective cation channel,
was detected after HAMLET treatment. Unlike membrane pores,
our whole cell patch clamp data show a marked time- and voltage-
dependent inactivation. Furthermore, the permeability profile of
the flux pathway is inconsistent with simple diffusion. Interestingly,
the biophysical and pharmacological characteristics of this channel
differ from those of classical TRP-, ENaC- or CNG channels and
the activation of the channel by HAMLET in excised membrane
patches appears to exclude signaling-dependent pathways such as
the formation of an ATP releasing pore leading to secondary
activation of ATP-sensitive ion channels, as seen for some toxins
[49]. In addition, compared to the Ca2+ ionophore A23187,
HAMLET caused a less drastic increase in [Ca2+]i and the
ionophore did not trigger a death response resembling that in
HAMET treated cells, including changes in morphology, con-
firming that in contrast to recent suggestions [50,51,52], HAM-
LET does not merely disrupt membrane integrity by fatty acid
delivery but triggers specific ion fluxes and a controlled cellular
response.
This study proposes that the activation of ion fluxes in response
to HAMLET may be conserved among cancer cells. Despite their
different origins, lung carcinoma, kidney carcinoma, cervical
carcinoma and lymphoma cells shared this response to HAMLET
and pharmacologic inactivation of ion fluxes rescued these cells
from HAMLET-induced death. The rapid kinetics of cell death in
response to HAMLET and the insensitivity to classical cell death
inhibitors [53] suggests that a new cell death modality might be
activated. The findings suggest that cation fluxes coupled to early
activation of the p38 MAPK signaling pathway may be involved
and potential candidates activated by p38 MAP kinase include a
Figure 6. p38 inhibition rescues carcinoma and lymphoma cells from death in response to HAMLET. (A, B) p38 MAPK inhibition
(SB202190, 20 mM, 30 minutes pre-incubation) rescued carcinoma (A549 and A498) and T-cell lymphoma (Jurkat) cells from death in response to
HAMLET (7–49 mM, 3 h). Viability was quantified by Trypan blue exclusion (A) or as ATP levels (B). Data are means6SEMs for 3 independent
experiments. The p38 inhibitor alone had no significant effect on cell death (leftmost bars in each graph). (C) Real-time images of cell morphology
after HAMLET exposure, showing that p38 inhibition prevents morphological changes in carcinoma cells (nuclear condensation, rounding up and
blebbing). Alexa-Fluor 568-labeled HAMLET is red and the nuclei are blue (Hoechst 33342). (D–E) A549 lung carcinoma cells were transfected using
siRNA against p38a and/or p38b or non-targeting siRNA and compared to non-transfected controls (NTF). Relative p38a and p38bmRNA levels are
shown (p38/GAPDH, in % of non-transfected cells) as means+SEMs for four independent experiments. Knockdown was also confirmed on the protein
level by western blotting against total p38 MAPK (representative blot shown, *p,0.05, ***p,0.001.). GAPDH was used as a loading control. (F) The
cytotoxic effect of HAMLET was quantified 48 hours after transfection as a reduction in ATP levels. Data are means+SEM for four independent
experiments. *p,0.05, ***p,0.001. For effects of the p38 inhibitor Birb0796, see Figure S6.
doi:10.1371/journal.pone.0058578.g006
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Figure 7. Ion channel inhibitors reduce protein phosphorylation. Amiloride or BaCl2 reduced phosphorylation of targets in the p38 signaling
Lung carcinoma cells were exposed to HAMLET (21 and 35 mM) for 1 hour, protein lysates were blotted, incubated with antibodies as noted in the
figure and quantified using ImageJ (Representative blot,+SEMs of 2–3 independent experiments). (A) Amiloride or BaCl2 (1 mM, 30 minutes
pretreatment) inhibited HAMLET-induced p38 MAPK phosphorylation (B) Amiloride and BaCl2 reverse the suppression of p-ERK1/2 phosphorylation
by HAMLET. (C) Difference in phosphorylation of p38 MAPK between normal differentiated cells (HRTEC) and kidney carcinoma cells, visualized by
phospho-specific antibodies.
doi:10.1371/journal.pone.0058578.g007
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Figure 8. Innate immune response to HAMLET in normal, differentiated cells. (A) The transcriptional response to HAMLET is qualitatively
different in normal cells (RPTEC), as shown by the heat map of genes with a log2 fold change .2 at any time point. (B) The number of differentially
expressed genes (log2 fold change $ 2) was reduced compared to carcinoma cells. (C) Seven innate immunity-related genes are upregulated in
normal cells, 75 minutes after HAMLET treatment. Two genes, p38 MAPK and MKK3/6, are downregulated. (D) Confirmation of the innate immune
response to HAMLET. Elevated TNF, IL-8 and IL-6 levels in supernatants of normal, differentiated cells, but not in carcinoma cells treated with HAMLET
(21–42 mM, 6 h). Data are means 6 SEMs of triplicates from 3 independent experiments. (E) The innate immune response of healthy cells (IL-6, IL-8
and TNF-a) was inhibited by amiloride and TNF-a expression by BaCl2. qRT-PCR quantification of cytokine mRNA-levels in normal, differentiated cells
exposed to HAMLET (35 mM, 1 hour).
doi:10.1371/journal.pone.0058578.g008
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wide range of kinases (including for example MAPKAPK2,
MNK1, and MSK1) as well as transcription factors (CHOP,
p53, ATF-1/2/6 and others). The effect of p38 inhibition was
limited to about six hours, however, reflecting the time of action of
the inhibitors or the involvement of additional, p38 independent
mechanisms that later overrule this pathway. Identifying these, as
yet unknown downstream effectors of the death response would be
of great significance to understand how the initiation of a response
at the membrane level may be transmitted into conserved cell
death signals.
Apoptotic cell death is associated with a decrease in [K+]i to 30–
50 mM [54,55,56]. The reduction of [K+]i is required for caspase
activation in Jurkat cells [55] as well as for DNA degradation [57].
Previously, decreased [K+]i and increased [Na
+]i were shown to
correlate with caspase-3 activation in cisplatin-induced apoptosis
of mammary cancer-derived cells [56]. Obviously, an increase in
Ca2+ and a net loss of osmolytes and volume is an early and
essential step in apoptotic cell death and this process involves the
opening of ion channels [55,58]. While these mechanistic links
between channel opening and apoptotic cell death are established,
HAMLET treated cells do not die by apoptosis. An apoptotic
response is activated but cell death is caspase independent,
proceeding with virtually similar kinetics in the presence of pan-
caspase inhibitors or in caspase 3-deficient cells [29]. Furthermore,
the characteristics of the channel activated by HAMLET have, to
our knowledge, never been described in this context.
The results further indicate that differences at the level of the
plasma membrane may distinguish normal differentiated cells
from tumor cells. Normal cells exhibited no detectable membrane
perturbations, a modest transcriptional response, mainly involving
innate immunity and no effect on p38 MAPK signaling. The
results also raise the question of whether the combined activation
of tumor cells and normal differentiated cells might result in
essential biological cooperativity. The innate immune response of
normal cells to HAMLET would ideally serve to activate cells that
scavenge and digest the remnants of dying cells and provide a
suitable immune environment for cancer cell removal. We
speculate that HAMLET’s efficiency as a selective tumoricidal
agent combined with the innate immune response of normal
differentiated cells may contribute to the low toxicity of HAMLET
in clinical studies as well as its beneficial effects. The ion channel-
dependent effector response in tumor cells accompanied by a
beneficial innate immune response in surrounding tissues may
serve as a two-tiered approach to killing cancer cells while
maintaining tissue integrity.
Supporting Information
Figure S1 HAMLET does not affect cyclic nucleotide-
gated (CNG) channels. (A) Current-voltage relationship of
cGMP activated currents in A549 cells. Using the ramp protocol
described in Materials and Methods, currents were measured
under standard conditions with an additional 1 mM 8Br-cGMP in
the pipette solution. Representative of 2 independent experiments
(B) Time dependent characteristics of the cGMP activated
currents. In the same cell as in A, time dependent characteristics
were investigated using a 1 s protocol stepping from 2100 mV to
+100 mV in 20 mV increments. Representative of two indepen-
dent experiments. (C–D) The CNG channel inhibitor L-cis-
diltiazem (LCD) does not inhibit HAMLET stimulated Ca2+
signaling. [Ca2+]i was measured using the Ca
2+ sensitive
fluorophore, Fura-2 (Molecular Probes). Cells grown on size #1
coverslips overnight were loaded 30 min with 4 mM Fura-2 in
normal growth medium before being installed in a microscope
perfusion chamber with constant perfusion with Krebs solution (in
mM: 150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 HEPES, 10
Glucose, pH 7.4 using NaOH). Fura-2 fluorescence of individual
cells was measured through a through a 406/1.4 NA oil
immersion objective (Olympus, Tokyo, Japan) using an Imic2000
microscope with a PolychromeV monochromator as the light
source (Till Photonics, Gra¨felfing, Germany), a Chroma 79001ET
filterset (Chroma Technology, Bellows Falls, VT, USA ), and
digitized by an Ixon 885 camera (Andor, Belfast, N. Ireland).
Signals between 470–550 nm following 20 ms excitation at
340 nm or 380 nm, were measured in 1 s intervals. Microscope
control, signal visualization and analysis were performed in Live
Acquisition software (Till Photonics). The presence of HAMLET
(35 mM) or LCD (200 mM) in the superfusate is indicated by the
top bar. Each trace indicates the Fura-2 ratio of an individual cell.
Representative of 2 independent experiments. (E) A549 lung
carcinoma cells were pretreated with L-cis-diltiazem (LCD) and
HAMLET-treated as shown. There was no significant inhibitory
effect of LCD on cell death.
(TIF)
Figure S2 Amiloride and BaCl2 rescue HeLa cells from
HAMLET-induced cell death. (A) Viability of HeLa cells after
exposure to HAMLET (21, 28 or 35 mM, 3 h), quantified by ATP
levels or Trypan blue exclusion. BaCl2 inhibited cell death but
GdCl3, Ruthenium Red had no effect (B) Amiloride inhibited the
tumoricidal effect of HAMLET but tetranidrine showed no effect.
(TIF)
Figure S3 Amiloride and BaCl2 rescue Jurkat cells from
HAMLET-induced cell death. Jurkat lymphoma cells were
pre-incubated with ion channel inhibitors as indicated and treated
with HAMLET (7–21 mM, 3 hours). Cell death was quantified by
trypan blue exclusion or ATP levels. (A) Amiloride or BaCl2
pretreated cells were rescued but GdCl2 had no effect (B)
Ruthenium Red or tetrandrine did not rescue the cells from
HAMLET –induced death. (C) Prolonged rescue (24 hours) by
amiloride and BaCl2 of A549 lung carcinoma cells treated with
HAMLET. (D) A combination of Amiloride and BaCl2 completely
rescued tumor cells from the lethal effects of HAMLET. Removal
of extra-cellular calcium did not reduce cell death. (E) Neither
inhibition of ER Ca2+ release by U73122, nor depletion of
extracellular Ca2+ by EDTA rescued the cells from HAMLET-
induced death.
(TIF)
Figure S4 Effect of ion channel inhibitors on HAMLET
uptake by lung carcinoma cells. Internalization of Alexa-568
fluor labeled HAMLET by tumor cells (35 mM, 1 hour, visualized
by epifluorescence microscopy. Amiloride or BaCl2 inhibited
internalization, leaving HAMLET associated with the cell surface.
WGA scale bar = 100 mm.
(TIF)
Figure S5 Differential expression of genes in the p38
MAPK-signaling pathway. A498 human kidney carcinoma
cells were exposed to HAMLET for three hours and differentially
expressed genes were functionally categorized using Ingenuity
Pathway Analysis. The p38-signaling pathway was identified as the
top-scoring pathway.
(TIF)
Figure S6 MAPK phosphorylation in response to HAM-
LET. (A) Lung carcinoma cells downregulate ERK1/2 and
activate p38a activity in response to HAMLET. (B) Kidney
carcinoma cells respond to HAMLET by phosphorylating p38a,
p38b and p38c as well as the downstream target HSP27, while
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ERK1/2 was dephosphorylated. Lysates of kidney carcinoma cells
(A498) exposed to HAMLET (35 mM) for 30 minutes. Membranes
with phospho-specific antibodies were probed with protein lysates
from HAMLET- or PBS-treated (control) carcinoma cells. Protein
phosphorylation was quantified using ImageJ. Data are means 6
SDs. (C) p38 inhibition by SB202190 abrogates phosphorylation
of p38 and HSP27. Lung carcinoma cells were preincubated with
SB202190 (20 mM, 30 minutes) and HAMLET-treated (35 mM,
30 minutes). (D) Normal, differentiated cells do not activate p38 in
response to HAMLET. Pediatric kidney cells in primary culture
were treated with HAMLET (49 mM, 30 minutes). (E) p38
inhibition (BIRB796, 10 mM) rescued carcinoma (A549 and A498)
cells from death in response to HAMLET (7–35 mM, 3 h).
Viability was quantified as ATP levels. (F) BIRB796 (10 mM)
diminishes the morphological changes associated with HAMLET-
induced cell death (35 mM, 3 h).
(TIF)
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